Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eli Lilly

768.91
+4.200.55%
Volume:1.55M
Turnover:1.19B
Market Cap:727.74B
PE:50.28
High:776.96
Open:760.11
Low:756.34
Close:764.71
52wk High:939.86
52wk Low:623.78
Shares:946.46M
Float Shares:945.00M
Volume Ratio:1.42
T/O Rate:0.16%
Dividend:5.80
Dividend Rate:0.75%
EPS(TTM):15.29
EPS(LYR):11.76
ROE:86.29%
ROA:16.55%
PB:39.83
PE(LYR):65.39

Loading ...

Eli Lilly's New Diabetes Drug Shows Better Blood Sugar, Weight Loss Results Than Rival

Dow Jones
·
Yesterday

Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says -- Barrons.com

Dow Jones
·
41 mins ago

Eli Lilly’s Orforglipron Shows Superior Results in Diabetes Trial

TIPRANKS
·
Yesterday

Data on Eli Lilly's Weight Loss Pill Hasn't Thrilled Investors. New Updates Are Complicating the Picture. -- Barrons.com

Dow Jones
·
Yesterday

Eli Lilly receives up to $8B contract from Veterans Affairs

TIPRANKS
·
Yesterday

GLP-1 drugs could save millions of lives - and spark a pension crisis

Dow Jones
·
Yesterday

Bernstein Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

TIPRANKS
·
Yesterday

Eli Lilly reports ‘positive’ results from ACHIEVE-3 Phase 3 trial

TIPRANKS
·
Yesterday

Lilly's Oral Glp-1, Orforglipron, Superior to Oral Semaglutide in Head-to-Head Trial

THOMSON REUTERS
·
Yesterday

Wisp: Expansion of Weight Care Vertical, Delivering Name-Brand Glp-1S Directly to Over 1.5 Mln Patients

THOMSON REUTERS
·
Yesterday

Wisp: Patients Can Access Weight Loss Treatments With Savings up to 50%, No Insurance Required

THOMSON REUTERS
·
Yesterday

Eli Lilly: Overall Safety & Tolerability Profile of Orforglipron in Achieve-3 Consistent With Previous Trials

THOMSON REUTERS
·
Yesterday

Eli Lilly: Positive Topline Results From Achieve-3 Evaluating Safety & Efficacy of Orforglipron VS Oral Semaglutide

THOMSON REUTERS
·
Yesterday

Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss?

Benzinga
·
Yesterday

Eli Lilly: Orforglipron Met Primary, All Key Secondary Endpoints Across Each Dose Comparison VS Oral Semaglutide

THOMSON REUTERS
·
Yesterday

Eli Lilly: for Primary Endpoint, Orforglipron Lowered a1c by 2.2% VS 1.4% With Oral Semaglutide at Highest Doses

THOMSON REUTERS
·
Yesterday

Wisp: Priced Ozempic, Wegovy, Mounjaro at $598, $558, $489 per Month, Respectively, Inclusive of Consultation, Monthly Follow-Ups, Doorstep Delivery

THOMSON REUTERS
·
Yesterday

Eli Lilly & Co: Promising Future Backed by Strong Pipeline and Positive Study Results

TIPRANKS
·
Yesterday

Citi Remains a Buy on Eli Lilly & Co (LLY)

TIPRANKS
·
Yesterday

Eli Lilly Cut to Hold From Buy by Berenberg

Dow Jones
·
Yesterday